G17DT IMMUNOGEN

Summary

G17Dt Immunogen (CHEMBL5095277) is a phase-3 clinical-stage unknown; indicated across 4 conditions including exocrine pancreatic carcinoma and gastric neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095277
Name	G17DT IMMUNOGEN
Type	Unknown
Max phase	3

Also known as: G17dt, G17dt (an antigastrin immunogen), G17dt immunogen, Gastrimmune, G17DT IMMUNOGEN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
gastric neoplasm	3	MONDO:0021085	MONDO:0001056
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	10
PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00020787	PHASE3	COMPLETED	Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
NCT00044031	PHASE3	COMPLETED	Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
NCT02118077	PHASE3	COMPLETED	Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer
NCT03200821	PHASE3	COMPLETED	An Open Label Study to Evaluate G17DT Compared to Gemcitabine
NCT02098239	PHASE2	COMPLETED	Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.
NCT02098291	PHASE2	COMPLETED	An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
NCT02181465	PHASE2	COMPLETED	Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.
NCT02223078	PHASE2	COMPLETED	Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.
NCT02228785	PHASE2	TERMINATED	A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer
NCT02233712	PHASE2	COMPLETED	Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.
NCT02450032	PHASE2	COMPLETED	Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer
NCT02518373	PHASE2	COMPLETED	Effect of G17DT in Patients With Stage II/III Colorectal Cancer
NCT02518529	PHASE2	COMPLETED	Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
NCT02521649	PHASE2	COMPLETED	Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).